Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Figure out How to Pick the Right Toothbrush for You - 2Rescuers attempt to dig free whale stranded on Germany's Baltic coast
- 3Met Gala 2026 will celebrate fashion as an 'embodied art form': A guide to the theme, dress code, cochairs and hosting committee of the starry event
- 4Defense Minister Katz moves to extend IDF service to 36 months
- 5Step by step instructions to Involve Compact disc Rates for Magnanimous Giving
- See the 'amazing' photos of Earth taken on historic Artemis II moon mission
- Nature's Best: A Manual for Beautiful Train Rides
- Language Learning Applications for Voyagers
- EU chief urges Iran to free imprisoned protesters, lift internet ban
- NASA’s Artemis II launch leaves Americans in awe: ‘We’re going to the frickin’ moon!’
- Winter storm warnings issued across Northeast as up to 9 inches of snow forecast; deadly atmospheric river in California snarls travel
- See the metal guts of a satellite in this wild X-ray view | Space photo of the day for Dec. 4, 2025
- Europe picks companies to help build Argonaut moon lander
- Israel faces widespread condemnation as NGO ban comes into effect
